Immediate Impact
84 standout
Citing Papers
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
Works of Fuad Ismail being referenced
Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Fuad Ismail | 90 | 42 | 31 | 87 | 58 | 31 | 328 | |
| Yun-Jau Chang | 109 | 83 | 37 | 67 | 35 | 18 | 290 | |
| Janine M. Davies | 202 | 82 | 24 | 62 | 86 | 40 | 362 | |
| Mark R. Openshaw | 85 | 50 | 41 | 31 | 49 | 26 | 333 | |
| Hedyeh Ebrahimi | 84 | 80 | 17 | 47 | 19 | 24 | 343 | |
| Ragheed Al-Mufti | 87 | 111 | 56 | 37 | 65 | 28 | 359 | |
| Gordon P. Watt | 60 | 20 | 15 | 79 | 25 | 26 | 281 | |
| Mingyang Chen | 98 | 50 | 13 | 42 | 33 | 30 | 337 | |
| Ariel Yuhan Ong | 107 | 33 | 35 | 43 | 13 | 34 | 333 | |
| Feng Ye | 93 | 38 | 15 | 38 | 15 | 29 | 282 | |
| Paola Pacetti | 178 | 81 | 51 | 53 | 32 | 23 | 363 |
All Works
Login with ORCID to disown or claim papers
Loading papers...